DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: Sitagliptin Phosphate/Metformin HCl (JANUMET®) (Drug)

Phase: N/A

Status: Terminated

Sponsored by: Merck Sharp & Dohme Corp.

Summary

The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET) from endocrinologists, diabetologists, internists, and general practitioners.

Clinical Details

Official title: Sitagliptin Phosphate/Metformin HCl (JANUMET) Post Marketing Surveillance Protocol

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome:

Number of Participants With an Adverse Event

Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl

Number of Participants With Concomitant Conditions

Number of Participants Taking Concomitant Medications

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Must be taking sitagliptin phosphate/metformin HCl (JANUMET®) for the treatment of

type 2 diabetes mellitus

- Treating physician must agree to provide information regarding the participant's

treatment

Locations and Contacts

Additional Information

Starting date: March 2009
Last updated: August 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017